Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
Acadia Pharmaceuticals (ACAD) reported strong financial results for Q4 and full year 2024, with total net product sales reaching $957.8 million, a 32% revenue growth. The company's two main products showed significant performance:
DAYBUE achieved Q4 sales of $96.7M and full-year sales of $348.4M, while NUPLAZID recorded Q4 sales of $162.9M and full-year sales of $609.4M. The company reported a net income of $226.5M for 2024, compared to a net loss of $61.3M in 2023.
For 2025, Acadia projects total revenues between $1.03-$1.095 billion, with NUPLAZID sales guidance of $650-690M and DAYBUE sales guidance of $380-405M. The company's cash position strengthened to $756.0M by end of 2024, up from $438.9M in 2023.
Acadia Pharmaceuticals (ACAD) ha riportato risultati finanziari solidi per il quarto trimestre e l'intero anno 2024, con vendite nette totali di 957,8 milioni di dollari, registrando una crescita del fatturato del 32%. I due principali prodotti dell'azienda hanno mostrato prestazioni significative:
DAYBUE ha raggiunto vendite nel quarto trimestre di 96,7 milioni di dollari e vendite annuali di 348,4 milioni di dollari, mentre NUPLAZID ha registrato vendite nel quarto trimestre di 162,9 milioni di dollari e vendite annuali di 609,4 milioni di dollari. L'azienda ha riportato un reddito netto di 226,5 milioni di dollari per il 2024, rispetto a una perdita netta di 61,3 milioni di dollari nel 2023.
Per il 2025, Acadia prevede ricavi totali tra 1,03 e 1,095 miliardi di dollari, con una guida alle vendite di NUPLAZID di 650-690 milioni di dollari e una guida alle vendite di DAYBUE di 380-405 milioni di dollari. La posizione di cassa dell'azienda è migliorata a 756,0 milioni di dollari entro la fine del 2024, rispetto ai 438,9 milioni di dollari nel 2023.
Acadia Pharmaceuticals (ACAD) reportó resultados financieros sólidos para el cuarto trimestre y el año completo 2024, con ventas netas totales de 957.8 millones de dólares, lo que representa un crecimiento del 32% en los ingresos. Los dos principales productos de la compañía mostraron un rendimiento significativo:
DAYBUE alcanzó ventas del cuarto trimestre de 96.7 millones de dólares y ventas anuales de 348.4 millones de dólares, mientras que NUPLAZID registró ventas del cuarto trimestre de 162.9 millones de dólares y ventas anuales de 609.4 millones de dólares. La compañía reportó un ingreso neto de 226.5 millones de dólares para 2024, en comparación con una pérdida neta de 61.3 millones de dólares en 2023.
Para 2025, Acadia proyecta ingresos totales entre 1.03 y 1.095 mil millones de dólares, con una guía de ventas de NUPLAZID de 650-690 millones de dólares y una guía de ventas de DAYBUE de 380-405 millones de dólares. La posición de efectivo de la compañía se fortaleció a 756.0 millones de dólares a finales de 2024, en comparación con 438.9 millones de dólares en 2023.
아카디아 제약 (ACAD)은 2024년 4분기 및 전체 연도에 대한 강력한 재무 결과를 보고했으며, 총 순제품 판매액은 9억 5780만 달러에 달하고, 이는 32%의 수익 성장률을 기록했습니다. 회사의 두 주요 제품은 상당한 성과를 보였습니다:
DAYBUE는 4분기 판매액 9,670만 달러 및 연간 판매액 3억 4840만 달러를 달성했으며, NUPLAZID는 4분기 판매액 1억 6290만 달러 및 연간 판매액 6억 940만 달러를 기록했습니다. 회사는 2024년 순이익이 2억 2650만 달러에 달한다고 보고했으며, 이는 2023년 6130만 달러의 순손실과 비교됩니다.
2025년을 위해 아카디아는 총 수익을 10억 3000만 달러에서 10억 9500만 달러 사이로 예상하며, NUPLAZID 판매 목표는 6억 5000만 달러에서 6억 9000만 달러, DAYBUE 판매 목표는 3억 8000만 달러에서 4억 500만 달러로 설정하고 있습니다. 회사의 현금 보유액은 2024년 말까지 7억 5600만 달러로 증가했으며, 이는 2023년 4억 3890만 달러에서 증가한 수치입니다.
Acadia Pharmaceuticals (ACAD) a annoncé de solides résultats financiers pour le quatrième trimestre et l'année complète 2024, avec des ventes nettes totales de 957,8 millions de dollars, ce qui représente une croissance des revenus de 32%. Les deux principaux produits de l'entreprise ont montré des performances significatives :
DAYBUE a réalisé des ventes de 96,7 millions de dollars au quatrième trimestre et de 348,4 millions de dollars sur l'ensemble de l'année, tandis que NUPLAZID a enregistré des ventes de 162,9 millions de dollars au quatrième trimestre et de 609,4 millions de dollars sur l'année. L'entreprise a déclaré un revenu net de 226,5 millions de dollars pour 2024, contre une perte nette de 61,3 millions de dollars en 2023.
Pour 2025, Acadia prévoit des revenus totaux compris entre 1,03 et 1,095 milliard de dollars, avec des prévisions de ventes pour NUPLAZID de 650 à 690 millions de dollars et des prévisions de ventes pour DAYBUE de 380 à 405 millions de dollars. La position de trésorerie de l'entreprise s'est renforcée pour atteindre 756,0 millions de dollars à la fin de 2024, contre 438,9 millions de dollars en 2023.
Acadia Pharmaceuticals (ACAD) hat starke finanzielle Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 gemeldet, mit einem Gesamtumsatz aus Produktverkäufen von 957,8 Millionen Dollar, was einem Umsatzwachstum von 32% entspricht. Die beiden Hauptprodukte des Unternehmens zeigten eine signifikante Leistung:
DAYBUE erzielte im vierten Quartal Verkäufe von 96,7 Millionen Dollar und im gesamten Jahr 348,4 Millionen Dollar, während NUPLAZID im vierten Quartal Verkäufe von 162,9 Millionen Dollar und im gesamten Jahr 609,4 Millionen Dollar verzeichnete. Das Unternehmen meldete für 2024 einen Nettogewinn von 226,5 Millionen Dollar, verglichen mit einem Nettverlust von 61,3 Millionen Dollar im Jahr 2023.
Für 2025 prognostiziert Acadia Gesamteinnahmen zwischen 1,03 und 1,095 Milliarden Dollar, mit einer Verkaufsprognose für NUPLAZID von 650-690 Millionen Dollar und einer Verkaufsprognose für DAYBUE von 380-405 Millionen Dollar. Die Liquiditätsposition des Unternehmens verbesserte sich bis Ende 2024 auf 756,0 Millionen Dollar, gegenüber 438,9 Millionen Dollar im Jahr 2023.
- 32% revenue growth to $957.8M in 2024
- Net income of $226.5M in 2024 vs loss in 2023
- Strong cash position of $756.0M, up from $438.9M
- DAYBUE sales grew 97% year-over-year
- NUPLAZID sales increased 11% year-over-year
- $150M gained from Priority Review Voucher sale
- Projected revenue growth to $1.03-1.095B in 2025
- R&D expenses increased 51% in Q4 2024
- SG&A expenses rose 17% in Q4 2024
- Projected increase in SG&A expenses to $535-565M for 2025
Insights
Acadia Pharmaceuticals delivered exceptionally strong financial results for 2024, with total revenue of
The company's transition to profitability is notable, posting net income of
Management's 2025 revenue guidance of
The
The clinical pipeline progression timelines indicate that 2026 will be a pivotal year, with potential readouts for both the Prader-Willi Syndrome and Alzheimer's disease psychosis programs, representing significant future growth catalysts beyond the current commercial portfolio.
Acadia's commercial portfolio continues to demonstrate exceptional strength, with DAYBUE's
The company's pipeline is strategically diversified across neuroscience and rare disease indications with high unmet needs. The Phase 3 COMPASS PWS study of ACP-101 in Prader-Willi Syndrome targets a condition affecting 15,000-20,000 patients in the US with treatment options. If successful, this could represent a
Acadia's expansion of ACP-204 into Lewy Body Dementia (LBD) Psychosis is particularly noteworthy. LBD affects approximately 1.4 million Americans, with psychosis occurring in up to
The in-licensing of ACP-711 for essential tremor demonstrates strategic pipeline building in neurology. Essential tremor affects approximately 7 million Americans, with current treatments (primarily beta-blockers and anti-seizure medications) providing inadequate symptom control in many patients. A selective GABAA-α3 positive allosteric modulator represents a novel mechanism potentially offering improved efficacy without the sedation associated with non-selective GABA modulators.
While the 2026 timeline for multiple clinical readouts creates a temporary gap in near-term catalysts, the company's strong commercial execution and
- 2024 total net product sales of
- Fourth quarter DAYBUE® (trofinetide) net product sales of
- Fourth quarter NUPLAZID® (pimavanserin) net product sales of
- Full year 2025 total revenue guidance of
“We closed 2024 on a strong note with each of our brands achieving record revenues in the fourth quarter and well-positioned for continued growth in 2025,” said Catherine Owen Adams, Chief Executive Officer. “To support this growth in 2025 we will continue investing in consumer activation to drive market share expansion for NUPLAZID in the US. We plan to expand our DAYBUE field force in the US and build our EU commercial team in anticipation of potentially launching trofinetide there next year. Beyond the growth of our commercial brands, our later-stage pipeline programs are advancing toward key milestones, including topline readouts starting in the first half of 2026, and our ongoing business development efforts continue to produce compelling opportunities like ACP-711 and other programs that we are excited to share more about at our inaugural R&D Day in June.”
Company Updates
- In January, the marketing authorization application for trofinetide was submitted to the European Medicines Agency (EMA) with expected approval in the first quarter of 2026.
-
In January, the Company provided timeline updates for its two most advanced clinical development programs:
- For the COMPASS PWS Phase 3 study of ACP-101 in Prader-Willi Syndrome, the last patient is expected to be enrolled in the fourth quarter of 2025, followed by the announcement of topline results in the first half of 2026.
- For the RADIANT Phase 2 study of ACP-204 in Alzheimer’s disease psychosis, the last patient is expected to be enrolled in the first quarter of 2026, followed by the announcement of topline results in mid-2026.
- In January, the Company announced plans for the initiation of a Phase 2 study of ACP-204 for a second indication in Lewy Body Dementia Psychosis in the third quarter of 2025.
-
In December 2024, the Company announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for
$150 million - In December 2024, the Company announced the appointment of Thomas Andrew Garner as Chief Commercial Officer.
- In November 2024, the Company announced an exclusive worldwide license agreement with Saniona for the development and commercialization of ACP-711, a potential first-in-class, highly selective GABAA-α3 positive allosteric modulator and plans to initiate a Phase 2 study in essential tremor in 2026.
Financial Results
Revenues
Total revenues comprising of net product sales from NUPLAZID and DAYBUE were
Net product sales of NUPLAZID were
Net product sales of DAYBUE were
Research and Development
Research and development expenses for the fourth quarter of 2024 were
Selling, General and Administrative
Selling, general and administrative expenses for the fourth quarter of 2024 were
Net Income (Loss)
For the fourth quarter of 2024, Acadia reported net income of
Cash and Investments
At December 31, 2024, Acadia’s cash, cash equivalents, and investment securities totaled
Full Year 2025 Financial Guidance
-
Total Revenues (
U.S. only) of$1.03 $1.09 5 billion -
NUPLAZID net product sales in the range of
$650 $690 million -
DAYBUE net product sales (
U.S. only) in the range of$380 $405 million -
R&D expense in the range of
$310 $330 million -
SG&A expense in the range of
$535 $565 million
Conference Call and Webcast Information
Acadia will host a conference call to discuss the fourth quarter and full year December 31, 2024 results today, Wednesday, February 26, 2025 at 1:30 p.m. PT/4:30 p.m. ET. The conference call may be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.
About NUPLAZID® (pimavanserin)
Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. These receptors are thought to play an important role in neuropsychiatric disorders. In vitro, pimavanserin demonstrated no appreciable binding affinity for dopamine (including D2), histamine, muscarinic, or adrenergic receptors. Pimavanserin was approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis by the
About DAYBUE® (trofinetide)
Trofinetide is a synthetic version of a naturally occurring molecule known as the tripeptide glycine-proline-glutamate (GPE). The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown. Trofinetide was approved for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older by the
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential,” “continue” and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) our business strategy, objectives and opportunities, including support for and innovations in our pipeline assets and business development opportunities, investments in consumer activation, expansion of our DAYBUE sales force in the US, and building of our EU commercial team, and potential for enhanced shareholder value; (ii) plans for, including timing, development and progress of commercialization or regulatory timelines for our products, including NUPLAZID and DAYBUE, and our product candidates; (iii) benefits to be derived from and efficacy of our products, including the potential advantages of our products; (iv) the timing and conduct of our clinical trials, including continued enrollment of our clinical trials in Prader-Willi syndrome and Alzheimer’s disease psychosis, the initiation of our clinical trial in Lewy Body Dementia Psychosis, and the timing and content of our presentations or announcements regarding our clinical trials; (v) our estimates regarding our future financial performance, profitability or capital requirements, including our full year 2025 financial guidance, and (vi) our ability to successfully complete additional business development transactions. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to: our dependency on the continued successful commercialization of our products and our ability to maintain or increase sales of our products; our plans to commercialize DAYBUE in
ACADIA PHARMACEUTICALS INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (Unaudited) |
||||||||||||||||
|
|
Three Months Ended
|
|
Years Ended
|
||||||||||||
|
|
2024 |
|
2023 |
|
|
2024 |
|
2023 |
|
||||||
Revenues |
|
|
|
|
|
|
|
|
||||||||
Product sales, net |
|
$ |
259,602 |
|
|
$ |
231,041 |
|
|
$ |
957,797 |
|
|
$ |
726,437 |
|
Total revenues |
|
|
259,602 |
|
|
|
231,041 |
|
|
|
957,797 |
|
|
|
726,437 |
|
Operating expenses |
|
|
|
|
|
|
|
|
||||||||
Cost of product sales (1)(2) |
|
|
21,803 |
|
|
|
17,891 |
|
|
|
81,841 |
|
|
|
41,638 |
|
Research and development (2) |
|
|
100,731 |
|
|
|
66,741 |
|
|
|
303,249 |
|
|
|
351,619 |
|
Selling, general and administrative (2) |
|
|
130,080 |
|
|
|
111,465 |
|
|
|
488,428 |
|
|
|
406,559 |
|
Gain on sale of non-financial asset |
|
|
(146,515 |
) |
|
|
— |
|
|
|
(146,515 |
) |
|
|
— |
|
Total operating expenses |
|
|
106,099 |
|
|
|
196,097 |
|
|
|
727,003 |
|
|
|
799,816 |
|
Income (loss) from operations |
|
|
153,503 |
|
|
|
34,944 |
|
|
|
230,794 |
|
|
|
(73,379 |
) |
Interest income, net |
|
|
7,007 |
|
|
|
4,759 |
|
|
|
25,458 |
|
|
|
17,234 |
|
Other income |
|
|
575 |
|
|
|
— |
|
|
|
1,823 |
|
|
|
5,109 |
|
Income (loss) before income taxes |
|
|
161,085 |
|
|
|
39,703 |
|
|
|
258,075 |
|
|
|
(51,036 |
) |
Income tax expense (benefit) |
|
|
17,343 |
|
|
|
(6,094 |
) |
|
|
31,624 |
|
|
|
10,250 |
|
Net income (loss) |
|
$ |
143,742 |
|
|
$ |
45,797 |
|
|
$ |
226,451 |
|
|
$ |
(61,286 |
) |
Earnings (net loss) per share: |
|
|
|
|
|
|
|
|
||||||||
Basic |
|
$ |
0.86 |
|
|
$ |
0.28 |
|
|
$ |
1.37 |
|
|
$ |
(0.37 |
) |
Diluted |
|
$ |
0.86 |
|
|
$ |
0.28 |
|
|
$ |
1.36 |
|
|
$ |
(0.37 |
) |
Weighted average common shares outstanding: |
|
|
|
|
|
|
|
|
||||||||
Basic |
|
|
166,535 |
|
|
|
164,812 |
|
|
|
165,717 |
|
|
|
163,819 |
|
Diluted |
|
|
166,696 |
|
|
|
166,510 |
|
|
|
166,362 |
|
|
|
163,819 |
|
|
|
|
|
|
|
|
|
|
||||||||
(1) Includes license fees and royalties |
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
||||||||
(2) Includes the following share-based compensation expenses |
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
||||||||
Cost of product sales, license fees and royalties |
|
$ |
421 |
|
|
$ |
363 |
|
|
$ |
1,319 |
|
|
$ |
1,007 |
|
Research and development |
|
$ |
2,395 |
|
|
$ |
4,707 |
|
|
$ |
14,100 |
|
|
$ |
17,408 |
|
Selling, general and administrative |
|
$ |
7,634 |
|
|
$ |
12,953 |
|
|
$ |
51,630 |
|
|
$ |
48,006 |
|
ACADIA PHARMACEUTICALS INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (Unaudited) |
||||||||
|
|
December 31,
|
|
|
December 31,
|
|
||
|
|
|
|
|
|
|
||
Assets |
|
|
|
|
|
|
||
Cash, cash equivalents and investment securities |
|
$ |
755,993 |
|
|
$ |
438,865 |
|
Accounts receivable, net |
|
|
98,739 |
|
|
|
98,267 |
|
Interest and other receivables |
|
|
5,956 |
|
|
|
4,083 |
|
Inventory |
|
|
21,949 |
|
|
|
35,819 |
|
Prepaid expenses |
|
|
55,681 |
|
|
|
39,091 |
|
Total current assets |
|
|
938,318 |
|
|
|
616,125 |
|
Property and equipment, net |
|
|
4,215 |
|
|
|
4,612 |
|
Operating lease right-of-use assets |
|
|
46,571 |
|
|
|
51,855 |
|
Intangible assets, net |
|
|
119,782 |
|
|
|
65,490 |
|
Restricted cash |
|
|
8,770 |
|
|
|
5,770 |
|
Long-term inventory |
|
|
69,741 |
|
|
|
4,628 |
|
Other assets |
|
|
359 |
|
|
|
476 |
|
Total assets |
|
$ |
1,187,756 |
|
|
$ |
748,956 |
|
Liabilities and stockholders’ equity |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
16,192 |
|
|
$ |
17,543 |
|
Accrued liabilities |
|
|
378,678 |
|
|
|
236,711 |
|
Total current liabilities |
|
|
394,870 |
|
|
|
254,254 |
|
Operating lease liabilities |
|
|
42,037 |
|
|
|
47,800 |
|
Other long-term liabilities |
|
|
18,056 |
|
|
|
15,147 |
|
Total liabilities |
|
|
454,963 |
|
|
|
317,201 |
|
Total stockholders’ equity |
|
|
732,793 |
|
|
|
431,755 |
|
Total liabilities and stockholders’ equity |
|
$ |
1,187,756 |
|
|
$ |
748,956 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20250226806678/en/
Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
ir@acadia-pharm.com
Media Contact:
Acadia Pharmaceuticals Inc.
Deb Kazenelson
(818) 395-3043
media@acadia-pharm.com
Source: Acadia Pharmaceuticals Inc.
FAQ
What was ACAD's total revenue growth in 2024?
How much revenue does ACAD expect from DAYBUE sales in 2025?
What were ACAD's Q4 2024 earnings results?
How did NUPLAZID sales perform in 2024 compared to 2023?
What is ACAD's cash position at the end of 2024?
